Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.27 Analyst target: $38.50 Upside: 1596.04%
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
See the full interactive analysis & chart →Informational only — not investment advice.